

The 10th Diabetes and Cancer Research Consortium (DCRC) workshop

Symposium

The Diabetes and Cancer Link: Lessons learned and current topics

Monday 16th September 2019

Jubileumsaulan, Jan Waldenströms gata 1, Malmö

PROGRAM		
08.00-08.30	Registration and coffee	
08.30-08.40	Welcome	Isabel Drake
08.40-09.00	EASD Diabetes and Cancer Study Group / Diabetes and Cancer Research Consortium "Future directions"	Andrew Renehan, Manchester University, UK
09.00-09.30	Epidemiology of diabetes and cancer: Lessons learned	Bendix Carstensen, Steno Diabetes Center, Denmark
09.30-10.00	Diabetes, insulin, and cancer: Mechanistic evidence	Michael Pollak, McGill University, Canada
10.00-10.30	Coffee break	
	<i>Heterogeneity of type 2 diabetes Chair: Paul Franks, Lund University</i>	
10.30-11.00	Novel subgroups of adult-onset diabetes and their association with outcomes: a data- driven cluster analysis of six variables	Emma Ahlqvist, Lund University Diabetes Centre, Sweden
11.00-11.30	Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis	Miriam S. Udler, Broad Institute/MGH, US
11.30-11.45	PanDIA-1 study: Early diagnosis of pancreatic cancer among subjects with new-onset diabetes	Immunovia, Lund, Sweden
11.45-12.00	The impact of type 2 diabetes on survival in patients with cancer independent of its effect on survival in individuals without cancer: a matched cohort analysis	Nasra Alam, Manchester University, UK
12.00-13.00	Lunch	
	<i>Diabetes, metabolic traits and cancer risk Chair: Sarah Wild, University of Edinburgh</i>	
13.00-13.30	What has been learned from Mendelian randomization studies?	Mattias Johansson, IARC, France
13.30-14.00	Obesity and smoking-related cancers: The Me-Can Study	Tanja Stocks, Lund University, Sweden
14.00-14.30	Obesity complications and breast cancer	Ann Rosendahl, Lund University, Sweden

14.30-15.00	Coffee break	
15.00-16.00	<i>Short presentations</i>	
	Diabetes Status and Mammographic Density as a Predictor of Breast Cancer Risk	Gertraud Maskarinec, University of Hawaii, US
	Body size and the risk and prognosis of prostate cancer: a pooled Swedish study	Sylvia Jochems, Lund University, Sweden
	Diabetes and prostate cancer	Danielle Crawley, King's College London, UK
	Type 1 diabetes and risk of cancer	Wuqing Huang, Lund University, Sweden
	End	

Background

Diabetes and cancer are common chronic diseases. In Europe alone, there are 55.4 million individuals living with diabetes, mainly type 2 diabetes; while there are an estimated 3.5 million new cancer cases per year. The two diseases co-occur more often than may be expected from their separate prevalence. The strength of the association between diabetes and cancer is different for different cancer types and it is still not fully explained.

Several potential mechanisms have been proposed and considered, including shared causes (e.g. obesity), interaction between mechanisms of importance for both diseases (e.g. insulin resistance, hyperinsulinemia, low grade inflammation), reverse causation (i.e. cancer causing diabetes), effects of diabetes treatments (e.g. insulin) and epidemiological biases that may appear in routine registers.

At the same time, the presence of diabetes often has an adverse effect on cancer treatment, making it important to consider both diseases together in clinical care.

Organisers and funders

The symposium is organised by the EASD Diabetes and Cancer Study Group (DCSG)/Diabetes and Cancer Research Consortium (DCRC), Andrew Renehan (Manchester University), and Isabel Drake (Lund University). The symposium is funded by the Crafoord Foundation, Stiftelsen för bekämpande av cancer vid Malmö Allmänna Sjukhus (MAS Cancer) and the Strategic Research Area (SRA) EpiHealth.

Registration

The symposium is targeted at clinicians and researchers at all levels interested in the link between diabetes, related traits and cancer. **Registration is mandatory.**

Register no later than 4 September 2019 to gunilla.hughes@med.lu.se wulkan@med.lu.se.

For any questions regarding the symposium, please contact Isabel.drake@med.lu.se.